Bayer Goes All In With Asundexian And Pulls Two Other Factor XIa Projects
Potential Xarelto Successor Prioritized
Despite promising mid-stage data for the Ionis-partnered fesomersen and osocimab, licensed from Aronora, the German major has plumped for asundexian as the priority compound for its Factor XIa efforts.
